ESMO Pre-"Research" Newsletter Atenolizumab: New Advances in the Field of Urinary Tumors

Abstract number: 1740P

：Bladder preservation therapy in combination with atezolizumab and radiation therapy for invasive bladder cancer (BPT-ART): An open-label, single-arm, multicenter, phase II trial

Radical cystectomy (RC) is the standard of care for patients with muscular invasive bladder cancer (BC) or high-risk non-muscular invasive BC

In this multicenter Phase II trial, investigators recruited patients

The researchers analyzed

Atenolizumab plus RT therapy has a higher pCR rate and is safer

Abstract number: 1742P

：Phase 2 study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC)

PolyADP ribose polymerase inhibitors (PARPi) modulate immunity by activating the innate immune pathway of cGAS/STING and inducing PD-L1 expression
.

The ARIANES study (EudraCT 2018-001744-62) evaluated the efficacy of PARPi lucarparil (R) in combination with the PD-L1 inhibitor atenizumab (A) in platinum-sensitive mUC and mCRPC cohorts
.

Patients recruited for mCRPC were treated with ≥ 2 androgen receptor pathway inhibitors (ARPi) but not PARPi
.

Patients receive lucapari (600 mg, BID) for a period of 3 weeks and then treatment with atenolizumab (1200 mg, q3wks) until the progression of
the disease.

The primary study endpoint was an objective response rate (ORR) at week 12 of treatment, with 3/16 of mUC patients and 9/24 of mCRPC patients expected to achieve an objective response to confirm that A+R regimens warrant further exploration
.

Secondary study endpoints were disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), safety, and biomarker analysis
assessed based on RECIST, iRECIST, and PCWG-3 criteria.

The study included a total of 16 patients with mUC and 24 patients
with mCRPC.

None of the patients had previously received anti-P-(L)1 therapy
.

Of these, 20 (83%) and 22 (92%) mCRPC patients received ARPI and chemotherapy, respectively; Nineteen cases with bone metastases
.

At week 12 of treatment, a total of 2 patients with mUC and 2 patients with mCRPC achieved objective remission
.

Other efficacy endpoints are shown in Figure 1
.

The most common grade 3 AEs are anemia (25%), fatigue (13%), and nausea/vomiting (10%)
.

Figure 1 Results of the study

Both groups of patients achieved some degree of tumor remission and disease control
.

In the mUC and mCRPC cohorts, 38% and 42% of the 12-week DCR, respectively, despite the fact that the ORR at week 12 was below the pre-specified threshold, could still indicate that the A+R regimen had better
antitumor activity in both groups of patients.

Further retrospective studies
of molecular typing of tumors are necessary in the future.

Reference source:Wang Mumu

Reviewed: LR

Execution: Small garden